Psoriasis is a chronic inflammatory immune-mediated disease, with an estimated prevalence of 2–4% in Europe. Recently, a new oral formulation of dimethyl fumarate (DMF) has been approved for treating adults with moderate-to-severe chronic plaque psoriasis. The aim of this multicentre retrospective study was to evaluate the effectiveness and safety of DMF in a real-life setting, through collecting and analysing data from DMF-treated patients with moderate-to-severe psoriasis
Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
Corazza, Monica;Odorici, Giulia;Borghi, Alessandro;
2023
Abstract
Psoriasis is a chronic inflammatory immune-mediated disease, with an estimated prevalence of 2–4% in Europe. Recently, a new oral formulation of dimethyl fumarate (DMF) has been approved for treating adults with moderate-to-severe chronic plaque psoriasis. The aim of this multicentre retrospective study was to evaluate the effectiveness and safety of DMF in a real-life setting, through collecting and analysing data from DMF-treated patients with moderate-to-severe psoriasisFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
